Table 2.

Solicited Injection Site and Systemic Adverse Events Reported by Participants Within 8 Days of Each Vaccination

	CD4 <200 cells/mL				CD4 ≥200 cells/mL
	15 μg HA		30 μg HA		15 μg HA		30 μg HA
Adverse Event	1st Dose	2nd Dose	1st Dose	2nd Dose	1st Dose	2nd Dose	1st Dose	2nd Dose
Systemic symptoms
≥1 symptom	14 (40%)	8 (24%)	14 (37%)	9 (27%)	24 (40%)	15 (25%)	24 (39%)	18 (30%)
Fevera	0	0	0	1 (3%)	0	1 (2%)	0	2 (3%)
Grade≥2				0		1 (2%)		0
Feverishnessb	4 (12%)	3 (9%)	3 (9%)	3 (9%)	7 (12%)	5 (9%)	3 (5%)	7 (12%)
Grade≥2	1 (3%)	1 (3%)	1 (3%)	1 (3%)	1 (2%)	2 (4%)	0	4 (7%)
Malaise	9 (26%)	5 (15%)	10 (28%)	3 (9%)	13 (22%)	9 (16%)	10 (16%)	11 (18%)
Grade≥2	3 (9%)	2 (6%)	5 (14%)	1 (3%)	6 (10%)	0	0	8 (13%)
Myalgia	5 (14%)	5 (15%)	7 (19%)	4 (12%)	9 (15%)	9 (17%)	13 (22%)	10 (16%)
Grade≥2	1 (3%)	2 (6%)	7 (19%)	0	3 (5%)	1 (2%)	1 (2%)	5 (8%)
Headache	7 (20%)	3 (9%)	11 (31%)	7 (21%)	17 (28%)	8 (15%)	15 (25%)	13 (22%)
Grade≥2	2 (6%)	0	6 (17%)	0	6 (10%)	0	4 (7%)	5 (9%)
Nausea	4 (12%)	3 (9%)	3 (9%)	3 (9%)	8 (13%)	4 (8%)	6 (10%)	6 (10%)
Grade≥2	1 (3%)	1 (3%)	3 (9%)	1 (3%)	2 (3%)	2 (4%)	2 (3%)	2 (3%)
Injection site symptoms
≥1 symptom	6 (17%)	3 (9%)	10 (28%)	7 (21%)	21 (32%)	21 (38%)	34 (42%)	25 (40%)
Grade ≥2	1 (3%)	0	0	0	2 (3%)	0	1 (2%)	1 (2%)
Pain	4 (12%)	1 (3%)	7 (19%)	3 (9%)	10 (16%)	7 (13%)	15 (25%)	13 (22%)
Grade ≥2	1 (3%)	0	0	0	2 (3%)	0	1 (2%)	1 (2%)
Tenderness	6 (17%)	1 (3%)	7 (19%)	6 (18%)	13 (22%)	10 (18%)	24 (39%)	19 (32%)
Grade ≥2	1 (3%)	0	0	0	0	0	0	1 (2%)
Redness	2 (6%)	1 (3%)	0	1 (3%)	10 (17%)	11 (20%)	13 (21%)	0
Grade ≥2	0	0		0	0	0	0
Swelling	2 (6%)	0	0	0	7 (12%)	8 (15%)	7 (11%)	0
Grade ≥2	0				0	0	0

Abbreviation: HA, hemagglutinin.

^aFever indicates a self-measured oral temperature of at least 38°C.

^bFeverishness indicates the participants’ self-reported sense of feverishness.